

# PathogenRX: Insuring your business for outbreaks, epidemics, and pandemics

PathogenRX provides indemnity protection that can compensate an insured in the event of a demonstrable loss, and can be tailored to provide coverage for specific expenses, geographies, types of disease, or portions of a calendar year.

The COVID-19 pandemic has demonstrated the potential devastating effect of infectious disease events on businesses and the economy. COVID-19, Zika, Ebola, MERS, SARS, and other recent viral outbreaks, epidemics, and pandemics have had widespread and profound effects on businesses across several industries, including hospitality, health care, real estate, travel, manufacturing, retail, and food and beverage. These events can be deadly and disruptive to businesses and their people, supply chains, and operations.

PathogenRX, developed by Marsh and Munich Re, is an insurance solution designed specifically for pandemic risk. The customizable policy provides financial protection against the fallout from an outbreak, epidemic, or pandemic, and is based on defined coverage triggers that allow for increased confidence in recovery of losses if the triggering event takes place.

## Costly risk, limited options

Outbreaks, epidemics, and pandemics are not like other risks. They may occur over several months or even longer, are often not confined to a specific region, and can be unpredictable. And unlike most other perils, they can scale and grow over time.

They can also be costly:

- The COVID-19 pandemic contributed to unprecedented financial market volatility, record levels of unemployment, and pervasive worries about a potential global recession. The International Monetary Fund [estimates](#) that in 2020, GDP fell 3.3% globally and 3.5% in the US.
- The 2014-15 West African Ebola epidemic cost the economies of Guinea, Liberia, and Sierra Leone an [estimated](#) \$2.8 billion, according to the World Bank.
- The 2015-16 Zika outbreak cost Latin American and Caribbean economies as much as \$18 billion, [according](#) to the United Nations Development Programme.

Yet companies have historically had few options for protecting against outbreaks, epidemics, and pandemics. Unlike natural catastrophes, these public health threats typically do not result in immediately identifiable physical damage, and calculating related losses can be difficult.

PathogenRX offers an innovative insurance solution for risks stemming from outbreaks, epidemics, and pandemics. Underwritten by Munich Re, PathogenRX enables companies to mitigate risk and enhance balance sheet protection in the event of an outbreak, epidemic, or pandemic.

## Robust, customizable coverage

A public health outbreak can lead to loss of gross profits, loss of revenue, and extra expense. PathogenRX can provide coverage for such losses incurred as a result of an infectious disease event in a designated geographical coverage area. Coverage is typically based on three straightforward triggers:

1. The World Health Organization (WHO) issues a Disease Outbreak Notice (DON) during the policy period.
2. The WHO issues a Public Health Emergency of International Concern for the disease specified in the DON.
3. A civil authority orders restrictions — including sheltering-in-place or partial or full cessation of business — for the area covered by the policy or a respective cluster of the insured's property.

All three triggers must be satisfied for the policy to respond.

Coverage under PathogenRX is provided on an occurrence basis; while the DON must be issued during the policy period, insured losses are typically covered if they take place within a year of the policy period's end.

## Innovative solution, extensive expertise

Multiyear options for PathogenRX can provide long-term price and capacity certainty. That can help companies protect themselves from future outbreaks, epidemics, and pandemics.

In addition to coverage under the policy, as a PathogenRX policyholder you will have access to a team of Marsh specialists who will work closely with you to understand your specific coverage needs. We will collaborate with specialists from Munich Re's epidemic risk solutions unit to structure the most suitable PathogenRX program for you. And in the case of a covered event, our experienced and dedicated claims specialists will be available to guide you through the claims process.

## Contacts



### Chad Wright

Managing Director  
Head of Alternative Risk Transfer  
North America  
Marsh  
**+1 404 995 2488**  
[chad.m.wright@marsh.com](mailto:chad.m.wright@marsh.com)



### Peter Lacovara

Senior Vice President  
Alternative Risk Transfer Leader  
Marsh  
**+1 415 743 8015**  
[peter.lacovara@marsh.com](mailto:peter.lacovara@marsh.com)

## Why Marsh?

Marsh's global network of risk specialists in more than 100 countries are focused on delivering solutions designed to preserve and grow capital for companies across many industries. Our colleagues have earned a reputation as leaders in providing risk and insurance services. Through forward-looking solutions and innovative products like PathogenRX, Marsh works with our clients to help them thrive through the effective management of their most critical risks, including pandemics, epidemics, and outbreaks.

## About Marsh

[Marsh](#) is the world's leading insurance broker and risk advisor. With around 40,000 colleagues operating in more than 130 countries, Marsh serves commercial and individual clients with data-driven risk solutions and advisory services. Marsh is a business of [Marsh McLennan](#) (NYSE: MMC), the world's leading professional services firm in the areas of risk, strategy and people. With annual revenue over \$17 billion, Marsh McLennan helps clients navigate an increasingly dynamic and complex environment through four market-leading businesses: [Marsh](#), [Guy Carpenter](#), [Mercer](#) and [Oliver Wyman](#). Follow Marsh on Twitter [@MarshGlobal](#); [LinkedIn](#); [Facebook](#); and [YouTube](#), or subscribe to [BRINK](#).

Marsh is one of the Marsh McLennan Companies, together with Guy Carpenter, Mercer, and Oliver Wyman. This document and any recommendations, analysis, or advice provided by Marsh (collectively, the "Marsh Analysis") are not intended to be taken as advice regarding any individual situation and should not be relied upon as such. The information contained herein is based on sources we believe reliable, but we make no representation or warranty as to its accuracy. Marsh shall have no obligation to update the Marsh Analysis and shall have no liability to you or any other party arising out of this publication or any matter contained herein. Any statements concerning actuarial, tax, accounting, or legal matters are based solely on our experience as insurance brokers and risk consultants and are not to be relied upon as actuarial, tax, accounting, or legal advice, for which you should consult your own professional advisors. Any modeling, analytics, or projections are subject to inherent uncertainty, and the Marsh Analysis could be materially affected if any underlying assumptions, conditions, information, or factors are inaccurate or incomplete or should change. Marsh makes no representation or warranty concerning the application of policy wording or the financial condition or solvency of insurers or reinsurers. Marsh makes no assurances regarding the availability, cost, or terms of insurance coverage. Although Marsh may provide advice and recommendations, all decisions regarding the amount, type or terms of coverage are the ultimate responsibility of the insurance purchaser, who must decide on the specific coverage that is appropriate to its particular circumstances and financial position.

1166 Avenue of the Americas, New York 10036

Copyright © 2021, Marsh LLC. All rights reserved. MA21-16117 726294708